EDIT vs NTLA Comparison: AI Score, Valuation, Performance and Upside
Compare Editas and Intellia Therapeutics by CRISPR vs base editing strategy, in vivo delivery progress, clinical pipeline advancement, partnership quality, and which gene editing company offers better long-term upside.
Use this Editas Medicine vs Intellia Therapeutics comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
NTLA holds the edge across 3 of 5 key metrics in this comparison. NTLA has delivered stronger 1-year price return (-16.04% vs -20.25%), though EDIT has the better forward P/E setup (-2.78x vs -6.10x for NTLA). Analyst consensus implies meaningfully more upside for NTLA (+143.86%) than for EDIT (+122.22%).
| Metric | EDIT | NTLA |
|---|---|---|
| AI score | 24.4 | 24.8 |
| AI rank | #3133 | #2986 |
| Latest close | $2.60 | $10.73 |
| 1M return | -7.14% | -30.77% |
| 6M return | +9.24% | -32.52% |
| 1Y return | -20.25% | -16.04% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EDIT | NTLA |
|---|---|---|
| 1Y ago | $7.98K (-20.2%) started 2025-07-24 | $8.4K (-16.0%) started 2025-07-24 |
| 5Y ago | $652.45 (-93.5%) started 2021-07-26 | $800.75 (-92.0%) started 2021-07-26 |
| 10Y ago | $982.99 (-90.2%) started 2016-07-25 | $5.77K (-42.3%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | EDIT | NTLA |
|---|---|---|
| Market cap | $399M | $1.5B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -2.78 | -6.10 |
| Price/Sales | 10.31 | 22.68 |
| EV/Revenue | 4.16 | 19.00 |
| Analyst target | $5.78 | $26.17 |
| Target upside | +122.22% | +143.86% |
| Metric | EDIT | NTLA |
|---|---|---|
| Revenue growth | -39.20% | -9.50% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -190.77% | -355.92% |
| Operating margin | N/A | N/A |
| Profit margin | -281.59% | 0.00% |
| ROIC proxy | -326.07% | -56.34% |
| Return on equity | -326.07% | -56.34% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 2.10 | 1.77 |
| Debt/equity | 392.40 | 12.96 |
| Current ratio | 3.22 | 6.10 |
| Quick ratio | 3.17 | 5.04 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | EDIT | NTLA |
|---|---|---|---|
| 1Y | Growth | -20.25% | -16.04% |
| CAGR | -20.26% | -16.05% | |
| Sharpe ratio | 0.15 | 0.30 | |
| Max drawdown | 59.88% | 71.27% | |
| Max daily drop | 15.57% | 42.23% | |
| Max wkly drop | 23.01% | 52.63% | |
| 5Y | Growth | -93.48% | -91.99% |
| CAGR | -42.11% | -39.68% | |
| Sharpe ratio | -0.19 | -0.31 | |
| Max drawdown | 98.66% | 96.45% | |
| Max daily drop | 35.63% | 42.23% | |
| Max wkly drop | 42.50% | 52.63% | |
| 10Y | Growth | -90.17% | -42.31% |
| CAGR | -20.71% | -5.35% | |
| Sharpe ratio | 0.07 | 0.27 | |
| Max drawdown | 98.92% | 96.45% | |
| Max daily drop | 35.63% | 42.23% | |
| Max wkly drop | 42.50% | 52.63% |
| Category | EDIT | NTLA |
|---|---|---|
| Company | EDIT | NTLA |
| Sector | N/A | N/A |
| Industry | N/A | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.